{
    "title": "108_s1780",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Anabolic Steroid Control Act of \n2003''.\n\nSEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.\n\n    (a) Definitions.--Section 102 of the Controlled Substances Act (21 \nU.S.C. 802) is amended--\n            (1) in paragraph (41)--\n                    (A) by realigning the margin so as to align with \n                paragraph (40);\n                    (B) by striking subparagraph (A) and inserting the \n                following:\n    ``(A) The term `anabolic steroid' means any drug or hormonal \nsubstance, chemically and pharmacologically related to testosterone \n(other than estrogens, progestins, corticosteroids, and \ndehydroepiandrosterone), and includes--\n            ``(i) androstanediol--\n                    ``(I) 3b,17b-dihydroxy-5a-androstane; and\n                    ``(II) 3a,17b-dihydroxy-5a-androstane;\n            ``(ii) androstanedione (5a-androstan-3,17-dione);\n            ``(iii) androstenediol--\n                    ``(I) 1-androstenediol (3b,17b-dihydroxy-5a-\n                androst-1-ene);\n                    ``(II) 1-androstenediol (3a,17b-dihydroxy-5a-\n                androst-1-ene);\n                    ``(III) 4-androstenediol (3b,17b-dihydroxy-androst-\n                4-ene); and\n                    ``(IV) 5-androstenediol (3b,17b-dihydroxy-androst-\n                5-ene);\n            ``(iv) androstenedione--\n                    ``(I) 1-androstenedione ([5a]-androst-1-en-3,17-\n                dione);\n                    ``(II) 4-androstenedione (androst-4-en-3,17-dione); \n                and\n                    ``(III) 5-androstenedione (androst-5-en-3,17-\n                dione);\n            ``(v) bolasterone (7a,17a-dimethyl-17b-hydroxyandrost-4-en-\n        3-one);\n            ``(vi) boldenone (17b-hydroxyandrost-1,4,-diene-3-one);\n            ``(vii) calusterone (7b,17a-dimethyl-17b-hydroxyandrost-4-\n        en-3-one);\n            ``(viii) clostebol (4-chloro-17b-hydroxyandrost-4-en-3-\n        one);\n            ``(ix) dehydrochlormethyltestosterone (4-chloro-17b-\n        hydroxy-17a-methyl-androst-1,4-dien-3-one);\n            ``(x) 4-dihydrotestosterone (17b-hydroxy-androstan-3-one);\n            ``(xi) drostanolone (17b-hydroxy-2a-methyl-5a-androstan-3-\n        one);\n            ``(xii) ethylestrenol (17a-ethyl-17b-hydroxyestr-4-ene);\n            ``(xiii) fluoxymesterone (9-fluoro-17a-methyl-11b,17b-\n        dihydroxyandrost-4-en-3-one);\n            ``(xiv) formebolone (2-formyl-17a-methyl-11a,17b-\n        dihydroxyandrost-1,4-dien-3-one);\n            ``(xv) furazabol (17a-methyl-17b-hydroxyandrostano[2,3-c]-\n        furazan);\n            ``(xvi) 18a-homo-17b-hydroxyestr-4-en-3-one (13b-ethyl-17b-\n        hydroxygon-4-en-3-one);\n            ``(xvii) 4-hydroxytestosterone (4,17b-dihydroxy-androst-4-\n        en-3-one);\n            ``(xviii) 4-hydroxy-19-nortestosterone (4,17b-dihydroxy-\n        estr-4-en-3-one);\n            ``(xix) mestanolone (17a-methyl-17b-hydroxy-5a-androstan-3-\n        one);\n            ``(xx) mesterolone (1a-methyl-17b-hydroxy-[5a]-androstan-3-\n        one);\n            ``(xxi) methandienone (17a-methyl-17b-hydroxyandrost-1,4-\n        dien-3-one);\n            ``(xxii) methandriol (17a-methyl-3b,17b-dihydroxyandrost-5-\n        ene);\n            ``(xxiii) methenolone (1-methyl-17b-hydroxy-5a-androst-1-\n        en-3-one);\n            ``(xxiv) methyltestosterone (17a-methyl-17b-hydroxyandrost-\n        4-en-3-one);\n            ``(xxv) mibolerone (7a,17a-dimethyl-17b-hydroxyestr-4-en-3-\n        one);\n            ``(xxvi) nandrolone (17b-hydroxyestr-4-en-3-one);\n            ``(xxvii) norandrostenediol--\n                    ``(I) 19-nor-4-androstenediol (3b, 17b-\n                dihydroxyestr-4-ene);\n                    ``(II) 19-nor-4-androstenediol (3a, 17b-\n                dihydroxyestr-4-ene);\n                    ``(III) 19-nor-5-androstenediol (3b, 17b-\n                dihydroxyestr-5-ene); and\n                    ``(IV) 19-nor-5-androstenediol (3a, 17b-\n                dihydroxyestr-5-ene);\n            ``(xxviii) norandrostenedione--\n                    ``(I) 19-nor-4-androstenedione (estr-4-en-3,17-\n                dione); and\n                    ``(II) 19-nor-5-androstenedione (estr-5-en-3,17-\n                dione;\n            ``(xxix) norbolethone (18a-homo-17b-hydroxypregna-4-en-3-\n        one);\n            ``(xxx) norclostebol (4-chloro-17b-hydroxyestr-4-en-3-one);\n            ``(xxxi) norethandrolone (17a-ethyl-17b-hydroxyestr-4-en-3-\n        one);\n            ``(xxxii) oxandrolone (17a-methyl-17b-hydroxy-2-oxa-[5a]-\n        androstan-3-one);\n            ``(xxxiii) oxymesterone (17a-methyl-4,17b-dihydroxyandrost-\n        4-en-3-one);\n            ``(xxxiv) oxymetholone (17a-methyl-2-hydroxymethylene-17b-\n        hydroxy-[5a]-androstan-3-one);\n            ``(xxxv) stanozolol (17a-methyl-17b-hydroxy-[5a]-androst-2-\n        eno[3,2-c]-pyrazole);\n            ``(xxxvi) stenbolone (17b-hydroxy-2-methyl-[5a]-androst-1-\n        en-3-one);\n            ``(xxxvii) testolactone (13-hydroxy-3-oxo-13,17-\n        secoandrosta-1,4-dien-17-oic acid lactone);\n            ``(xxxviii) 1-testosterone (17b-hydroxy-5a-androst-1-en-3-\n        one);\n            ``(xxxix) testosterone (17b-hydroxyandrost-4-en-3-one);\n            ``(xl) tetrahydrogestrinone (13b,17a-diethyl-17b-\n        hydroxygon-4,9,11-trien-3-one);\n            ``(xli) trenbolone (17b-hydroxyestr-4,9,11-trien-3-one); \n        and\n            ``(xlii) any salt, ester, or ether of a drug or substance \n        described in this paragraph.''; and\n                    (C) by adding at the end the following:\n    ``(C) Notwithstanding subparagraph (A), the Attorney General may \nnot schedule Androstenedione as a controlled substance in accordance \nwith this Act until the Attorney General receives a finding from the \nCommissioner of Food and Drugs relating to whether Androstenedione is \nlawfully marketed under the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 321 et seq.).''; and\n            (2) in paragraph (44), by inserting ``anabolic steroids,'' \n        after ``marihuana,''.\n    (b) Authority and Criteria for Classification.--Section 201(g) of \nthe Controlled Substances Act (21 U.S.C. 811(g)) is amended--\n            (1) in paragraph (1), by striking ``substance from a \n        schedule if such substance'' and inserting ``drug which \n        contains a controlled substance from the application of titles \n        II and III of the Comprehensive Drug Abuse Prevention and \n        Control Act (21 U.S.C. 802 et seq.) if such drug''; and\n            (2) in paragraph (3), by adding at the end the following:\n            ``(C) Upon the recommendation of the Secretary of Health \n        and Human Services, a compound, mixture, or preparation which \n        contains any anabolic steroid, which is intended for \n        administration to a human being or an animal, and which, \n        because of its concentration, preparation, formulation or \n        delivery system, does not present any significant potential for \n        abuse.''.\n    (c) Anabolic Steroids Control Act.--Section 1903 of the Anabolic \nSteroids Control Act of 1990 (Public Law 101-647) is amended--\n            (1) by striking subsection (a); and\n            (2) by redesignating subsections (b) and (c) as subsections \n        (a) and (b), respectively.\n\nSEC. 3. SENTENCING COMMISSION GUIDELINES.\n\n    The United States Sentencing Commission shall--\n            (1) review the Federal sentencing guidelines with respect \n        to offenses involving anabolic steroids;\n            (2) consider amending the Federal sentencing guidelines to \n        provide for increased penalties with respect to offenses \n        involving anabolic steroids in a manner that reflects the \n        seriousness of such offenses and the need to deter anabolic \n        steroid use; and\n            (3) take such other action that the Commission considers \n        necessary to carry out this section.\n\nSEC. 4. PREVENTION AND EDUCATION PROGRAMS.\n\n    (a) In General.--The Secretary of Health and Human Services \n(referred to in this Act as the ``Secretary'') shall award grants to \npublic and nonprofit private entities to enable such entities to carry \nout science-based education programs in elementary and secondary \nschools to highlight the harmful effects of anabolic steroids.\n    (b) Eligibility.--\n            (1) Application.--To be eligible for grants under \n        subsection (a), an entity shall prepare and submit to the \n        Secretary an application at such time, in such manner, and \n        containing such information as the Secretary may require.\n            (2) Preference.--In awarding grants under subsection (a), \n        the Secretary shall give preference to applicants that intend \n        to use grant funds to carry out programs based on--\n                    (A) the Athletes Training and Learning to Avoid \n                Steroids program;\n                    (B) the Athletes Targeting Healthy Exercise and \n                Nutrition Alternatives program; and\n                    (C) other programs determined to be effective by \n                the National Institute on Drug Abuse.\n    (c) Use of Funds.--Amounts received under a grant under subsection \n(a) shall be used primarily for education programs that will directly \ncommunicate with teachers, principals, coaches, as well as elementary \nand secondary school children concerning the harmful effects of \nanabolic steroids.\n    (d) Authorization of Appropriations.--There is authorized to be \nappropriated to carry out this section, $15,000,000 for each of fiscal \nyears 2004 through 2009.\n\nSEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.\n\n    (a) In General.--The Secretary of Health and Human Services shall \nensure that the National Survey on Drug Use and Health includes \nquestions concerning the use of anabolic steroids.\n    (b) Authorization of Appropriations.--There is authorized to be \nappropriated to carry out this section, $1,000,000 for each of fiscal \nyears 2004 through 2009."
}